Report forecast the global hospital infection
therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.
Hospital-acquired diseases are also known as
nosocomial infections that are acquired in hospitals and other healthcare
facilities. These infections are classified only when a patient is admitted for
reasons other than the infections and are caused by bacteria, fungi, parasites,
or viruses. Most common types of hospital-acquired infections are SSIs, UTIs,
bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal
illnesses.
These infections appear between 48 hours and four
days after a patient is admitted and are usually related to a treatment of
procedure used to treat or diagnose the patient's initial illness or injury.
Hospital-acquired diseases are preventable through adherence to strict
guidelines and less usage of invasive equipment that must be followed by
healthcare professionals while caring for the patient.
Anti-infective drugs are used for the treatment of
these infections. These infections can be minimized by following proper
infection control measures in the hospitals and healthcare institutions.
The report covers the present scenario and growth
prospects of the global hospital infection therapeutics market for the period
2015-2019. To calculate the market size, the report considers revenue generated
from the sales of drugs used in the treatment of various hospital-acquired
infections such as bloodstream infections, Clostridium difficile infections,
hospital-acquired pneumonia, surgical site infections, and urinary tract
infections.
According to the report, surgeries for cardiac,
renal, and gastrointestinal disorders and cesarean section for childbirth are
commonly performed currently. Many individuals also choose esthetic enhancement
surgeries such as maxillofacial and prosthetic surgeries. This leads to
increased exposure to microbes in the hospital environment, thus leading to infections
and other complications. Surgeries increase the length of stay in the hospital
and individuals are at greater risk of contracting infections.
Further, the report states that generic drugs are
similar in quality, dosage form, strength, and efficacy to branded drugs, but
are available at lower prices. A branded drug can be manufactured as generic
after losing its patent. Many of the anti-infective drugs such as ceftriaxone,
ampicillin, ampicillin and sulbactam, and ertapenem, are available as generics
in the market.
Global Hospital Infection Therapeutics Market
2015-2019, has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the Americas, APAC, and EMEA;
it also covers the landscape of the global hospital infection therapeutics
market and its growth prospects in the coming years. The report includes a
discussion of the key vendors operating in this market.
key players in the Global Hospital Infection
Therapeutics Market: Allergan, Bayer,
GlaxoSmithKline, Merck and Pfizer
Other Prominent Vendors in the market are: Abbott
Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals,
AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals,
Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological
Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar,
Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company,
and Valneva.
Key regions
- Americas
- APAC
- EMEA
Key market driver
- Development of multidrug resistant variants
- For a full, detailed list, view our report
Key market challenge
- Rise in number of infection control programs
- For a full, detailed list, view our report
Key market trend
- Patient assistance programs
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 83 pages, 40 Exhibits “Global
Hospital Infection Therapeutics Market 2015-2019” report covers Executive
summary, Scope of the report, Market research methodology, Introduction, Market
landscape, Disease overview, Pipeline analysis, Market segmentation by drug
class, Market segmentation by type of infections, Geographical segmentation,
Market drivers, Impact of drivers, Market challenges, Market trends, Vendor
landscape, Key vendor analysis, Appendix.
For
further information on this report, please visit- http://mrr.cm/oMW
Related Reports are:
1st - Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 - See
more at - http://mrr.cm/oMm
2nd - Global Head and Neck Cancer Diagnostics Market 2015-2019 - See more at -
http://mrr.cm/oMs
3rd - Global Viral Hepatitis and Retrovirus Diagnostic Tests Market 2015-2019
- See more at - http://mrr.cm/oMe
